Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Now dermatologists are increasingly prescribing the drug Rogaine, known generically as minoxidil, in low-dose pills to help ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Penumbra PEN is gaining traction in the U.S. and international markets on strong customer uptake of its Lightning Bolt and Flash lines. Yet, unfavorable currency movements and rising expenses are ...

Hologic HOLX has been gaining from new strategic product launches across Diagnostics and Breast Health. However, ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Hims & Hers Health. If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...